Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2025
Psychiatry and Mental health journal rankings 2025
139 ranked journals · Subfield in Medicine
Psychiatry and Mental health has 139 ranked journals in 2025. The median journal has an OJR of 0.88, below the world average of 1.00, up 0.05 on 2024; Q1 starts at OJR 1.19. The two highest-scoring journals with stable ranks are The Lancet Healthy Longevity and Alzheimer s & Dementia: each is likely ranked within the top 3.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
Show all 42 subfields
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
139 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #3 of 139The Lancet Healthy LongevityOAElsevier BV · United Kingdom | 3.73Q1 | 11.39 3.39 up from 2024 | 377 | 100% | $6,680 | Rising vs field, 2022–25 | |
Rank 2; likely between #1 and #3 of 139Alzheimer s & DementiaWiley · United States | 3.72Q1 | 11.57 1.60 up from 2024 | 1,539 | 100% | $4,200 | ||
Rank 3; likely between #2 and #5 of 139Alzheimer s Research & TherapyOABioMed Central · United Kingdom | 3.09Q1 | 9.29 0.61 up from 2024 | 663 | 100% | $4,290 | ||
Rank 4; likely between #3 and #8 of 139The Journal of Headache and PainOASpringer Nature · Italy | 2.63Q1 | 9.47 0.63 up from 2024 | 533 | 100% | $3,990 | ||
Rank 5; likely between #4 and #9 of 139CNS DrugsAdis, Springer Healthcare · New Zealand | 2.59Q1 | 7.87 0.85 down from 2024 | 232 | 63% | $5,090 | Rising vs field, 2022–25 | |
Rank 6; likely between #2 and #11 of 139The Journal of Prevention of Alzheimer s DiseaseOASpringer Science+Business Media · Switzerland | 2.56Q1 | 7.08 0.29 down from 2024 | 385 | 100% | $4,060 | ||
Rank 7; likely between #3 and #11 of 139General PsychiatryOABMJ · United Kingdom | 2.52Q1 | 7.08 0.48 up from 2024 | 200 | 100% | — | ||
Rank 8; likely between #4 and #10 of 139JMIR AgingOACanada | 2.48Q1 | 5.29 0.13 up from 2024 | 302 | 100% | $1,605 | ||
Rank 9; likely between #7 and #12 of 139EpilepsiaWiley · Denmark | 2.13Q1 | 5.55 1.18 down from 2024 | 982 | 76% | $4,360 | ||
Rank 10; likely between #5 and #20 of 139Alzheimer s & Dementia Translational Research & Clinical InterventionsOAElsevier BV · United States | 2.03Q1 | 6.33 0.57 down from 2024 | 266 | 100% | $2,540 | ||
Rank 11; likely between #8 and #21 of 139Annals of General PsychiatryOABioMed Central · United Kingdom | 1.89Q1 | 6.23 2.56 up from 2024 | 158 | 100% | $3,090 | ||
Rank 12; likely between #9 and #25 of 139Neurology and TherapyOAAdis, Springer Healthcare · United Kingdom | 1.73Q1 | 4.92 0.18 down from 2024 | 348 | 100% | $7,400 | Rising vs field, 2022–25 | |
Rank 13; likely between #10 and #21 of 139Current Pain and Headache ReportsSpringer Science+Business Media · United States | 1.71Q1 | 5.76 1.46 up from 2024 | 307 | 20% | $4,590 | ||
Rank 14; likely between #11 and #21 of 139CephalalgiaSAGE Publishing · United Kingdom | 1.70Q1 | 6.41 1.29 up from 2024 | 357 | 100% | $3,000 | ||
Rank 15; likely between #9 and #33 of 139Therapeutic Advances in PsychopharmacologyOASAGE Publishing · United Kingdom | 1.69Q1 | 6.46 1.43 up from 2024 | 103 | 100% | $2,650 | ||
Rank 16; likely between #10 and #28 of 139Neurologic ClinicsElsevier BV · United States | 1.68Q1 | 4.25 0.57 up from 2024 | 161 | 7% | $3,650 | ||
Rank 17; likely between #11 and #22 of 139Schizophrenia BulletinOxford University Press · United Kingdom | 1.68Q1 | 5.74 0.98 up from 2024 | 523 | 78% | $4,981 | ||
Rank 18; likely between #11 and #23 of 139Alzheimer s & Dementia Diagnosis Assessment & Disease MonitoringOAElsevier BV · United States | 1.66Q1 | 4.35 0.62 down from 2024 | 385 | 100% | $2,540 | ||
Rank 19; likely between #12 and #27 of 139Acta Psychiatrica ScandinavicaWiley · United Kingdom | 1.56Q1 | 4.36 0.33 down from 2024 | 346 | 74% | $4,880 | ||
Rank 20; likely between #12 and #31 of 139The Journal of Clinical PsychiatryPhysicians Postgraduate Press, Inc. · United States | 1.53Q1 | 3.18 0.61 down from 2024 | 458 | 17% | — | ||
Rank 21; likely between #15 and #30 of 139SchizophreniaOASpringer Science+Business Media | 1.50Q1 | 4.90 0.25 up from 2024 | 319 | 100% | $3,890 | ||
Rank 22; likely between #17 and #33 of 139Expert Review of NeurotherapeuticsTaylor & Francis · United Kingdom | 1.43Q1 | 4.55 0.65 up from 2024 | 283 | 45% | — | ||
Rank 23; likely between #11 and #52 of 139Digital BiomarkersOAKarger Publishers · Switzerland | 1.42Q1 | 3.05 1.20 down from 2024 | 51 | 100% | $990 | ||
Rank 24; likely between #14 and #39 of 139International Journal of Bipolar DisordersOASpringer Science+Business Media · Germany | 1.41Q1 | 5.02 1.14 up from 2024 | 113 | 100% | $2,990 | ||
Rank 25; likely between #19 and #32 of 139Aging & Mental HealthRoutledge · United Kingdom | 1.40Q1 | 3.21 0.43 up from 2024 | 556 | 48% | — | ||
Rank 26; likely between #19 and #42 of 139European Archives of Psychiatry and Clinical NeuroscienceSpringer Science+Business Media · Germany | 1.33Q1 | 3.91 0.11 down from 2024 | 570 | 47% | $2,990 | ||
Rank 27; likely between #21 and #41 of 139European NeuropsychopharmacologyElsevier BV · Netherlands | 1.32Q1 | 4.65 0.31 up from 2024 | 451 | 17% | $3,000 | ||
Rank 28; likely between #19 and #46 of 139The International Journal of NeuropsychopharmacologyOAUniversity of Oxford · United Kingdom | 1.31Q1 | 4.44 0.23 up from 2024 | 210 | 100% | $2,693 | ||
Rank 29; likely between #19 and #48 of 139Psychiatry and Clinical NeurosciencesWiley · Australia | 1.30Q1 | 4.01 0.14 down from 2024 | 325 | 64% | $3,240 | ||
Rank 30; likely between #16 and #55 of 139American Journal of Alzheimer s Disease & Other Dementias®OASAGE Publishing · United Kingdom | 1.29Q1 | 3.81 0.52 up from 2024 | 94 | 100% | $2,650 | ||
Rank 31; likely between #23 and #45 of 139DementiaSAGE Publishing · United Kingdom | 1.27Q1 | 2.91 0.06 up from 2024 | 305 | 81% | $3,650 | ||
Rank 32; likely between #25 and #42 of 139International Journal of Geriatric PsychiatryWiley · United Kingdom | 1.26Q1 | 3.25 0.25 up from 2024 | 476 | 73% | $4,600 | ||
Rank 33; likely between #27 and #47 of 139Epilepsia OpenOAWiley · United States | 1.21Q1 | 3.72 0.73 up from 2024 | 485 | 100% | $3,120 | ||
Rank 34; likely between #27 and #53 of 139Neurology Clinical PracticeLippincott Williams & Wilkins · United States | 1.20Q1 | 3.24 0.48 up from 2024 | 370 | 88% | — | Rising vs field, 2022–25 | |
Rank 35; likely between #23 and #56 of 139Journal of Psychiatry and NeuroscienceOACanadian Medical Association · Canada | 1.19Q1 | 4.03 1.14 up from 2024 | 134 | 100% | — | ||
Rank 36; likely between #23 and #59 of 139Journal of Alzheimer s Disease ReportsOAIOS Press · Netherlands | 1.19Q2 | 3.40 0.11 up from 2024 | 305 | 100% | — | ||
Rank 37; likely between #7 and #109 of 139Journal of Medical HumanitiesSpringer Science+Business Media · Netherlands | 1.19Q2 | 0.97 0.85 down from 2024 | 126 | 49% | $3,190 | ||
Rank 38; likely between #11 and #95 of 139Dementia and Neurocognitive DisordersOASouth Korea | 1.17Q2 | 3.96 1.61 up from 2024 | 62 | 100% | — | ||
Rank 39; likely between #26 and #59 of 139NeuropsychologyAmerican Psychological Association · United States | 1.16Q2 | 2.87 0.31 down from 2024 | 188 | 50% | — | ||
Rank 40; likely between #24 and #61 of 139Developmental Medicine & Child NeurologyWiley · United Kingdom | 1.16Q2 | 2.52 0.45 down from 2024 | 809 | 78% | $5,300 | ||
Rank 41; likely between #28 and #59 of 139Journal of Attention DisordersSAGE Publishing · United States | 1.14Q2 | 3.87 1.25 up from 2024 | 351 | 61% | $3,650 | ||
Rank 42; likely between #35 and #52 of 139Brain and BehaviorOAWiley · United States | 1.13Q2 | 3.09 0.10 down from 2024 | 1,320 | 100% | $3,630 | ||
Rank 43; likely between #29 and #62 of 139American Journal of Geriatric PsychiatryElsevier BV · United States | 1.13Q2 | 2.99 0.74 up from 2024 | 485 | 19% | $4,400 | Falling vs field, 2022–25 | |
Rank 44; likely between #32 and #55 of 139Neuropsychiatric Disease and TreatmentOADove Medical Press · New Zealand | 1.13Q2 | 3.33 0.03 up from 2024 | 728 | 100% | $2,836 | ||
Rank 45; likely between #26 and #63 of 139Journal of Geriatric Psychiatry and NeurologySAGE Publishing · United States | 1.13Q2 | 3.16 0.18 up from 2024 | 127 | 52% | $4,150 | ||
Rank 46; likely between #39 and #53 of 139Journal of Alzheimer s DiseaseIOS Press · Netherlands | 1.09Q2 | 3.34 0.13 up from 2024 | 2,258 | 36% | — | Falling vs field, 2022–25 | |
Rank 47; likely between #29 and #67 of 139International Journal of Sexual HealthRoutledge · United States | 1.09Q2 | 2.55 0.33 up from 2024 | 132 | 88% | — | ||
Rank 48; likely between #24 and #76 of 139Current Sexual Health ReportsSpringer Science+Business Media · United States | 1.08Q2 | 3.55 0.91 up from 2024 | 74 | 50% | $4,090 | ||
Rank 49; likely between #39 and #59 of 139Journal of Psychosomatic ResearchElsevier BV · United States | 1.07Q2 | 3.22 0.27 down from 2024 | 713 | 39% | $3,760 | ||
Rank 50; likely between #36 and #60 of 139Expert Opinion on PharmacotherapyTaylor & Francis · United Kingdom | 1.07Q2 | 3.47 0.77 up from 2024 | 543 | 31% | — |
7 Psychiatry and Mental health journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1Neurology Clinical PracticeLippincott Williams & Wilkins · United States+106% vs groupOJR 0.62 → 1.20range +66% to +154%
- 2The Lancet Healthy LongevityOAElsevier BV · United Kingdom+58% vs groupOJR 2.53 → 3.73range +18% to +110%
- 3Neurology and TherapyOAAdis, Springer Healthcare · United Kingdom+55% vs groupOJR 1.19 → 1.73range +16% to +108%
- 4Early Intervention in PsychiatryWiley · United Kingdom+36% vs groupOJR 0.78 → 0.99range +13% to +64%
- 5CNS DrugsAdis, Springer Healthcare · New Zealand+38% vs groupOJR 2.01 → 2.59range +12% to +70%
- 6Clinical EpileptologySpringer Science+Business Media · Germany+86% vs groupOJR 0.12 → 0.21range +5.5% to +228%
- 7PsychogeriatricsWiley · United Kingdom+27% vs groupOJR 0.67 → 0.79range +2.2% to +57%
No-label zone, -9.1% to +10%Group median changeBar scale -71% to +248% (ratio scale)
14 Psychiatry and Mental health journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Journal of Pediatric Rehabilitation MedicineOAIOS Press · Netherlands-49% vs groupOJR 0.77 → 0.37range -65% to -27%
- 2Progress in Neurology and PsychiatryWiley · United Kingdom-62% vs groupOJR 0.40 → 0.14range -81% to -24%
- 3Sexual MedicineOAElsevier BV · United Kingdom-27% vs groupOJR 1.23 → 0.84range -40% to -11%
- 4American Journal of Geriatric PsychiatryElsevier BV · United States-31% vs groupOJR 1.74 → 1.13range -47% to -10%
- 5Sexual Medicine ReviewsElsevier BV · United States-31% vs groupOJR 1.38 → 0.89range -49% to -8.4%
- 6Headache The Journal of Head and Face PainWiley · United States-26% vs groupOJR 1.42 → 0.98range -40% to -7.9%
- 7Journal of Alzheimer s DiseaseIOS Press · Netherlands-14% vs groupOJR 1.36 → 1.09range -21% to -6.7%
- 8The Journal of Sexual MedicineElsevier BV · United Kingdom-17% vs groupOJR 1.29 → 1.00range -29% to -3.5%
- 9Applied Neuropsychology ChildTaylor & Francis · United States-28% vs groupOJR 0.88 → 0.59range -47% to -3.4%
- 10Journal of Clinical PsychopharmacologyLippincott Williams & Wilkins · United States-21% vs groupOJR 0.65 → 0.48range -37% to -2.4%
- 11Revista de Psiquiatría y Salud MentalElsevier BV · Spain-39% vs groupOJR 1.16 → 0.66range -62% to -1.9%
- 12Developmental NeurorehabilitationTaylor & Francis · United Kingdom-25% vs groupOJR 0.68 → 0.48range -43% to -1.6%
- 13Pediatric NeurologyElsevier BV · United States-18% vs groupOJR 1.09 → 0.83range -33% to -1.2%
- 14Current Alzheimer ResearchBentham Science Publishers · Netherlands-21% vs groupOJR 0.89 → 0.66range -37% to -0.1%
No-label zone, -9.1% to +10%Group median changeBar scale -83% to +482% (ratio scale)
Subfields of Medicine, with Psychiatry and Mental health highlighted.
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
13 additional Psychiatry and Mental health journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 139
- Window papers (baseline)
- 79,078 +3.1% from indicator year 2022
- Median OJR
- 0.88 -5.1% from indicator year 2022
- Rising journals (2025)
- 7
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 65 | 71 | 74 | 82 | 82 | 87 | 89 | 93 | 98 | 100 | 102 | 107 | 109 | 119 | 119 | 123 | 134 | 142 | 141 | 142 | 140 | 145 | 147 | 144 | 144 | 139 | |
| Window papers (baseline) | 20,748 | 23,511 | 25,742 | 27,920 | 29,159 | 31,333 | 33,934 | 37,512 | 41,192 | 44,742 | 46,739 | 49,131 | 50,177 | 52,432 | 55,064 | 58,021 | 60,510 | 61,715 | 63,841 | 65,471 | 68,365 | 72,111 | 76,708 | 78,267 | 78,465 | 79,078 | |
| Median OJR | 0.82 | 0.772 | 0.79 | 0.767 | 0.87 | 0.8329 | 0.89 | 0.929 | 0.92 | 0.996 | 0.95 | 1.03 | 1.013 | 0.964 | 1.0034 | 1.009 | 0.982 | 0.959 | 0.976 | 0.985 | 1.0031 | 0.907 | 0.928 | 0.911 | 0.8335 | 0.88 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.